Avdoralimab (DrugBank: Avdoralimab)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 162 | 類天疱瘡（後天性表皮水疱症を含む。） | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04563923 (ClinicalTrials.gov) | October 10, 2020 | 17/9/2020 | Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody | Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody | Bullous Pemphigoid | Drug: Avdoralimab (IPH5401);Other: Control | Centre Hospitalier Universitaire de Nice | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 2 | France |
| 2 | EUCTR2020-002912-34-FR (EUCTR) | 11/08/2020 | 22/06/2020 | Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody | Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody - PB | Auto Immune bullous Diseases;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: avdoralimab Product Code: IPH5401 INN or Proposed INN: avdoralimab Other descriptive name: NNC0215-0384 | CHU NICE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | France |